EUVIMEDEUVIMED entdecken
Crossref

A β-Carboline Derivate PAD4 Inhibitor Reshapes Neutrophil Phenotype and Improves the Tumor Immune Microenvironment against Triple-Negative Breast Cancer

Di Zhu iD, Yu Lu, Zhanchao Yan, Qian Deng, Bo Hu, Yinsong Wang iD, Wenjing Wang, Yanming Wang, Yuji Wang iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Di Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing 100069, P. R. China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Carbolines, Protein-Arginine Deiminase Type 4, Tumor Microenvironment. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: China Scholarship Council, Beijing Laboratory of Oral Health, Beijing Municipal Colleges and Universities High Level Talents Introduction and Cultivate Project???Beijing Great Wall Scholar Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer is a highly aggressive and heterogeneous breast cancer subtype characterized by early metastasis, poor prognosis, and high recurrence. Targeting histone citrullination-mediated chromatin dysregulation to induce epigenetic alterations shows great promise in TNBC therapy. We report the synthesis, optimization, and evaluation of a novel series of β-carboline-derived peptidyl arginine deiminase 4 inhibitors that exhibited potent inhibition of TNBC cell proliferation. The most outstanding PAD4 inhibitor, compound 28, hindered the PAD4-H3cit-NET signaling pathway and inhibited the growth of solid tumors and pulmonary metastatic nodules in the 4T1 in situ mouse model. Furthermore, 28 improved the tumor immune microenvironment by reshaping neutrophil phenotype, upregulating the proportions of dendritic cells and M1 macrophages, and reducing the amount of myeloid-derived suppressor cells. In conclusion, our work offered 28 as an efficacious PAD4 inhibitor that exerts a combination of conventional chemotherapy and immune-boosting effects, which represents a potential therapy strategy for TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCarbolinesProtein-Arginine Deiminase Type 4Tumor MicroenvironmentNeutrophilsAntineoplastic AgentsAnimalsFemaleHumansMiceCell Line, TumorCell ProliferationMice, Inbred BALB CEnzyme InhibitorsPhenotypeStructure-Activity Relationship

Substanzen

CarbolinesProtein-Arginine Deiminase Type 4Antineoplastic AgentsPADI4 protein, humanEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing 100069, P. R. China.
  • Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing 100069, P…
  • The First Affiliated Hospital of Henan University, Center for Clinical Research and Translational Medicine, Laboratory of Epigenetics, Henan University, Kaifeng 475004, P. R. China.
  • The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Key Laboratory on Technologies Enabl…
  • Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, P. R. China.
  • Beijing Laboratory of Oral Health, Capital Medical University, Beijing 100069, P. R. China.

ORCID-Profile: Di Zhu, Yinsong Wang, Yuji Wang

Förderung

  • China Scholarship Council
  • Beijing Laboratory of Oral Health
  • Beijing Municipal Colleges and Universities High Level Talents Introduction and Cultivate Project???Beijing Great Wall Scholar Program
  • Capital Medical University Scientific Research Cultivating Fund

Zitieren

APA

Zhu, D., Lu, Y., Yan, Z., Deng, Q., Hu, B., Wang, Y., Wang, W., Wang, Y., & Wang, Y. (2024). A β-Carboline Derivate PAD4 Inhibitor Reshapes Neutrophil Phenotype and Improves the Tumor Immune Microenvironment against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00030

Vancouver

Zhu D, Lu Y, Yan Z, Deng Q, Hu B, Wang Y, et al. A β-Carboline Derivate PAD4 Inhibitor Reshapes Neutrophil Phenotype and Improves the Tumor Immune Microenvironment against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00030

BibTeX
@article{Zhu2024,
  author = {Zhu, Di and Lu, Yu and Yan, Zhanchao and Deng, Qian and Hu, Bo and Wang, Yinsong and Wang, Wenjing and Wang, Yanming and Wang, Yuji},
  title = {A β-Carboline Derivate PAD4 Inhibitor Reshapes Neutrophil Phenotype and Improves the Tumor Immune Microenvironment against Triple-Negative Breast Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00030}
}
Kostenlos starten →